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Interstitial cystitis/bladder pain syndrome (IC/BPS) remains a clinical enigma.  Estimated to 
affect over 8 million women globally (3, 19), it is a challenge to diagnose and to treat 
effectively, due to an unknown etiology and complex, poorly understood pathophysiology. 
Clinical diagnosis is symptom-based, with patients experiencing debilitating chronic pelvic or 
bladder pain, pressure or discomfort, along with urinary storage symptoms including 
frequency and urgency(10). IC/BPS is also associated with depression and anxiety(8).  
 
Current treatments for IC/BPS are varied, and include diet and lifestyle changes, intravesical 
instillations directly into the bladder, oral medications, and as a last resort surgery.  Generally, 
success rates for therapeutic interventions are modest at best and there is little consensus 
with respect to which is the most effective.  Intravesical dimethyl sulfoxide therapy has been 
widely used for decades, alone or as part of a cocktail in combination with other agents such 
as local anesthetics(15). However, long-term outcomes are poorly documented. In a recent 
study intravesical DMSO/heparin/hydrocortisone therapy was only moderately effective for 
treatment of IC/BPS, with only half (56%) of patients well or significantly improved at 5 
years(13). A better understanding of the pathophysiology of this condition could potentially 
lead to the identification of novel pharmacological targets and the development of more 
successful treatments. As such there has been extensive research focused on unravelling the 
underlying mechanisms of IC/BPS. Locally within the bladder wall, known key pathological 
changes include urothelium disruption, impaired barrier function and inflammation. These, in 
addition to sensitized peripheral and central neural pathways, all contribute to pain and 
urinary symptoms(15). There is also convincing epidemiological evidence supporting the link 
between IC/BPS and a history of urinary tract infection(16) and activation of the innate 
immune system.  
 Toll-like receptors (TLR) are a family of membrane glycoproteins expressed primarily on cells 
of the immune system that act as pattern recognition molecules. They can bind pathogen-
derived molecules and mediate signaling cascades leading to an inflammatory response(12). 
Our understanding of TLRs has expanded greatly from their role in immune cells into their 
role in non-immune cells and tissues, and they have become an area of recent interest in 
inflammatory disorders of the lower urinary tract.  Whilst there has been some focus on TLR7 
in IC/BPS, where TLR7 expression was found to be upregulated in bladder biopsies from 
Hunner-type (ulcerative) IC patients, and a TLR7 agonist increased expression of TLR7 mRNA 
and induced cystitis in mice(11), the field is not well researched. TLR4 is expressed on 
urothelial cells(21) and it’s role in mediating inflammation following infection of the bladder 
has been well established for some time(2). Schrepf and colleagues have shown that TLR4 
inflammatory responses in PBMCs are a marker of widespread pain in IC/BPS(22).  However, 
until now the role of TLR4 in IC/BPS was not well understood.  
 
In a recent issue of the American Journal of Physiology-Renal Physiology, de Oliveira et al. 
(2018) elegantly demonstrate for the first time, and at both a molecular and functional level, 
that TLR4 plays a central role in initiating cyclophosphamide-induced bladder dysfunction and 
inflammation(9). In this study, convincing evidence is provided that genetic deletion, using 
TLR4-/- mice, or pharmacological inhibition of TLR4 with the selective antagonist resatorvid, 
prevents dysfunction in micturition and inflammatory events associated with cystitis. This 
data directly demonstrates for the first time important etiological information regarding CYP-
induced–cystitis, in the increased expression of TLR4 downstream signaling MyD88 and TRIF, 
which supports an important role for this receptor.   
 A key finding, that is possibly somewhat underplayed in the manuscript, is the identification 
of a role for TLR4 in normal bladder function, shown in the untreated TLR4-/- mice, which 
displayed different voiding profiles with increased frequency of non-voiding contractions. This 
suggests that TLR4 signaling impacts the afferent arm of micturition, and it will be interesting 
in future studies to determine whether this is via a direct effect on afferent nerves per se or 
an indirect effect via the release of mediators from the urothelium, which is a source of 
inflammatory peptides and cytokines(14). Since other endogenous ligands can activate TLR4, 
including ECM components, heat shock proteins and β-defensins(18), other physiological 
roles for TLR4 in normal bladder control may yet be uncovered. 
 
A confounding factor in our progress in understanding the pathophysiology of IC/BPS has 
been the limitations of the different animal models employed, recently brought to the 
forefront in an excellent review by Birder and Andersson(4). IC/BPS is complex and there are, 
as yet, no animal models available that mimic all aspects of the human experience. In the 
study by de Oliveira et al. the well-established cyclophosphamide (CYP)-induced mouse 
model of acute cystitis was used, in which urotoxicity results in pain-related behavior, altered 
micturition patterns and bladder overactivity, as well as inflammation(5, 6), all traditional 
features of ICS/BPS.  Whilst it is important to acknowledge the limitations of such animal 
models, they remain important for the elucidation of important pathological and mechanistic 
information, contributing to the big picture of IC/BPS. Interestingly, it is becoming more 
widely acknowledged that IC and BPS are two separate disorders, cystitis as an inflammatory 
disease and BPS as a pain syndrome, and, as such, information gleaned from the different 
animal models may aid this differentiation, to the benefit of future diagnosis and treatments.  
Overall, the article by de Oliveira et al. makes a significant contribution to our knowledge of 
IC/BPS and potential treatment of the condition. Whilst several immunosuppressive agents 
are under investigation as potential treatments for IC/BPS, and some have been trialed(1), 
this research opens up an alternative avenue in a field where is a limited arsenal.  Blockade 
of TLRs is still in the experimental phase, but has great potential, especially given that the 
selective TLR4 antagonist used in the de Oliveira et al. study, TAK-242 (resatorvid), has already 
been as far as phase III clinical trials for the treatment of severe sepsis(17). This study provides 
solid rationale for the use of TLR4 antagonists for IC, and if the positive findings in the mouse 
model can be translated into the clinical setting this may be an attractive treatment in an IC 
cohort. However, many other agents have failed clinically due to systemic adverse effects, 
thus intravesical treatment using an innovative delivery system such as liposome-based 
administration may be an attractive avenue to investigate in the basic setting and clinically.  
Conversely, systemic factors may play a role in the pathology of some patients or some types 
of IC/BPS, particularly BPS, which is now being considered more of a pain syndrome linked to 
other co-morbidities such as irritable bowel syndrome(7).  The question that now addressing 
is whether TLR4 is involved in central pain pathways of BPS and whether blockade of TLR4 will 
be effective in patients with these phenotypes. TLR4 have been shown to activate TRPV1 
receptors(20), and given the sensory/urgency aspects of IC/BPS, new agents that target the 
afferent limb of micturition would be welcome.  
 
Thus IC/BPS is a debilitating condition, yet we have only a limited understanding of the 
pathophysiology involved.  This has resulted in the current treatments lacking efficacy in many 
patients and the need for new treatments acting via novel mechanisms. The demonstration 
of a role for TLR4 in IC/BPS opens up possible new avenues for drug development for this 
condition. 
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